Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology

BACKGROUND: An antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used for clinical purposes. ERCC1 is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy. High ERCC1 expression is linked to drug resistance on cisplatin-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Donghui, Baruch, Dror, Shu, Youmin, Yuan, Kehu, Sun, Zairen, Ma, Kaiyan, Hoang, Toan, Fu, Wei, Min, Li, Lan, Zhu-Sheng, Wang, Fangxun, Mull, Lori, He, Wei-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526464/
https://www.ncbi.nlm.nih.gov/pubmed/23171216
http://dx.doi.org/10.1186/1472-6750-12-88

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526464/
https://www.ncbi.nlm.nih.gov/pubmed/23171216
http://dx.doi.org/10.1186/1472-6750-12-88

Ejemplares similares